ReviewCancers2021
Photosensitizing Medications and Skin Cancer: A Comprehensive Review.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Association between prescribed antidepressant medication and skin cancer (melanoma, basal cell carcinoma and cutaneous squamous cell carcinoma) risk: a systematic review and meta-analysis.Skin health and disease · 2026Review
- Perceptions and Management of Pregnancy-Related Skin Changes: A Cross-Sectional Study on Knowledge, Practices, and Use of Skincare Product.Journal of cosmetic dermatology · 2025Article
- Photosensitizing Drugs and Risk of Skin Cancer in Women-A Prospective Population-Based Study.Photodermatology, photoimmunology & photomedicine · 2025Article
- Personalized Photoprotection: Expert Consensus and Recommendations From a Delphi Study Among Dermatologists.Photodermatology, photoimmunology & photomedicine · 2025Article
- A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA's adverse events reporting system.Archives of dermatological research · 2024Article
- The phenomenon of phototoxicity and long-term risks of commonly prescribed and structurally diverse drugs.Journal of photochemistry and photobiology · 2024Article
- Clinical Applications ofLife (Basel, Switzerland) · 2023Review
- Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study.Acta dermato-venereologica · 2023Article
- Etiologies of Melanoma Development and Prevention Measures: A Review of the Current Evidence.Cancers · 2021Review
- Evaluation of the Association Between Statin Exposure and Skin Cancer: A Nationwide Case-Control Study in South Korea.Indian journal of dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) The incidence of skin cancer is increasing in the United States (US) despite scientific advances in our understanding of skin cancer risk factors and treatments. In vitro and in vivo studies have provided evidence that suggests that certain photosensitizing medications (PSMs) increase skin cancer risk. This review summarizes current epidemiological evidence on the association between common PSMs and skin cancer. (2) A comprehensive literature search was conducted to identify meta-analyses, observational studies and clinical trials that report on skin cancer events in PSM users. The associated risks of keratinocyte carcinoma (squamous cell carcinoma and basal cell carcinoma) and melanoma are summarized, for each PSM. (3) There are extensive reports on antihypertensives and statins relative to other PSMs, with positive and null findings, respectively. Fewer studies have explored amiodarone, metformin, antimicrobials and vemurafenib. No studies report on the individual skin cancer risks in glyburide, naproxen, piroxicam, chlorpromazine, thioridazine and nalidixic acid users. (4) The research gaps in understanding the relationship between PSMs and skin cancer outlined in this review should be prioritized because the US population is aging. Thus the number of patients prescribed PSMs is likely to continue to rise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.